REAL-WORLD DISABILITY AND BURDEN AMONG PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Author(s)
Cécile Gousset, PharmD1, Ekaterina Smolkina, MA2, Guillaume Montagu, Msc1, Beth Poirrette, MSc3, Yasmin Taylor, MSc3, Jack Wright, MSc3.
1Patient-Driven Medicines Development, Sanofi, Gentilly, France, 2Health Economics and Value Assessment, Sanofi Genzyme, Amsterdam, Netherlands, 3Adelphi Real World, Bollington, United Kingdom.
1Patient-Driven Medicines Development, Sanofi, Gentilly, France, 2Health Economics and Value Assessment, Sanofi Genzyme, Amsterdam, Netherlands, 3Adelphi Real World, Bollington, United Kingdom.
OBJECTIVES: Immunoglobulin therapy (Ig) is widely considered standard-of-care for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This analysis explored the relationship between disability and burden of CIDP in patients that had residual disability after Ig.
METHODS: Secondary data analysis of the Adelphi CIDP Disease Specific Programme™, a cross-sectional survey of neurologists and their patients with CIDP across China, France, Germany, Italy, Japan, Spain, the UK, and USA (September 2022-April 2023). Physicians reported on INCAT score, and caregiver utilization. The same patients provided information on I-RODS, FACIT-Fatigue, EQ-5D-5L and EQ-VAS measures. Patients diagnosed with typical, motor, or multifocal CIDP, and had adjusted INCAT ≥2 were included. Patients were considered inadequately controlled if they were prescribed Ig for ≥6 months (Analysis A; linear/logistic regression) or refractory if they had previously been in receipt of Ig for ≥6 months but discontinued (Analysis B; Pearson’s r correlation).
RESULTS: Analysis A (n=230): Mean (SD) patient age was 56.2 (12.8), 61% were male. For every point increase in INCAT, the odds of requiring a caregiver increased by 1.77 (n=199; p=0.003), and caregiving hours per week increased by 3.6 hours (n=77; p=0.028). For each point increase in INCAT there was a decrease in I-RODs (-4.9; p<0.001), FACIT-fatigue (-3.2; p<0.001), EQ-5D-5L (-0.113; p<0.001) and EQ-VAS, (-5.7; <0.001). Analysis B (n=53): Mean (SD) patient age was 57.2 (11.7), 58% were male. Significant correlations were observed between INCAT and caregiver utilization (n=47; r=0.43; p<0.001), caregiver hours (n=20; r=0.45, p=0.05), FACIT-fatigue (n=25; r=-0.46, p=0.02), and EQ-VAS (n=25; r=-0.47, p=0.02), and not observed for I-RODs (n=21; r=-0.40, p=0.07) and EQ-5D-5L (n=25; r=-0.39, p=0.06).
CONCLUSIONS: Increased disability was significantly associated with greater patient burden and caregiver utilization. The impact on quality of life and caregiving demands underscore reduction of disability, and subsequent downstream consequences, as a key therapeutic target for novel interventions.
METHODS: Secondary data analysis of the Adelphi CIDP Disease Specific Programme™, a cross-sectional survey of neurologists and their patients with CIDP across China, France, Germany, Italy, Japan, Spain, the UK, and USA (September 2022-April 2023). Physicians reported on INCAT score, and caregiver utilization. The same patients provided information on I-RODS, FACIT-Fatigue, EQ-5D-5L and EQ-VAS measures. Patients diagnosed with typical, motor, or multifocal CIDP, and had adjusted INCAT ≥2 were included. Patients were considered inadequately controlled if they were prescribed Ig for ≥6 months (Analysis A; linear/logistic regression) or refractory if they had previously been in receipt of Ig for ≥6 months but discontinued (Analysis B; Pearson’s r correlation).
RESULTS: Analysis A (n=230): Mean (SD) patient age was 56.2 (12.8), 61% were male. For every point increase in INCAT, the odds of requiring a caregiver increased by 1.77 (n=199; p=0.003), and caregiving hours per week increased by 3.6 hours (n=77; p=0.028). For each point increase in INCAT there was a decrease in I-RODs (-4.9; p<0.001), FACIT-fatigue (-3.2; p<0.001), EQ-5D-5L (-0.113; p<0.001) and EQ-VAS, (-5.7; <0.001). Analysis B (n=53): Mean (SD) patient age was 57.2 (11.7), 58% were male. Significant correlations were observed between INCAT and caregiver utilization (n=47; r=0.43; p<0.001), caregiver hours (n=20; r=0.45, p=0.05), FACIT-fatigue (n=25; r=-0.46, p=0.02), and EQ-VAS (n=25; r=-0.47, p=0.02), and not observed for I-RODs (n=21; r=-0.40, p=0.07) and EQ-5D-5L (n=25; r=-0.39, p=0.06).
CONCLUSIONS: Increased disability was significantly associated with greater patient burden and caregiver utilization. The impact on quality of life and caregiving demands underscore reduction of disability, and subsequent downstream consequences, as a key therapeutic target for novel interventions.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR247
Topic
Clinical Outcomes, Patient-Centered Research, Study Approaches
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Neurological Disorders, No Additional Disease & Conditions/Specialized Treatment Areas, Rare & Orphan Diseases